RadNet (RDNT) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue grew 9.2% year-over-year to $471.4 million, despite a $22 million negative impact from severe weather and wildfires; adjusted EBITDA declined 20.6% to $46.4 million, with a $15 million weather-related impact.

• Net loss widened to $37.9 million from $2.8 million year-over-year, primarily due to higher operating expenses and increased stock-based compensation.

• Advanced imaging volumes increased, with PET/CT up nearly 23% and a notable shift toward higher-margin procedures, especially for prostate and brain studies.

• Digital Health segment revenue rose 31.1% to $19.2 million, driven by 33.3% AI revenue growth and informatics product expansion.

• Announced definitive agreement to acquire iCAD, Inc. to accelerate global leadership in AI-powered breast health solutions, expected to close in Q2 or Q3 2025.

Financial highlights

• Service fee revenue increased to $439.3 million, up from $397.2 million year-over-year; capitation revenue was $32.1 million.

• Operating expenses rose 16.8% to $470.2 million, driven by higher salaries, stock-based compensation, and medical supplies.

• Cash and cash equivalents were $717 million at quarter end; net debt to adjusted EBITDA slightly above 1x.

• Adjusted EBITDA margin for Q1 2025 was 9.8%, down from 13.5% in Q1 2024.

• Cash provided by operating activities was $41.5 million; capital expenditures were $48.8 million.

Outlook and guidance

• 2025 revenue and adjusted EBITDA guidance ranges increased by $10 million and $3 million, respectively, reflecting strong post-disruption trends; revised guidance to $1,835–$1,885 million revenue and $268–$276 million adjusted EBITDA.

• Digital Health segment guidance unchanged: $80–$90 million revenue, $15–$17 million adjusted EBITDA.

• Capital expenditure budget guidance raised by $5 million.

• Free cash flow for Imaging Center segment expected at $70–$80 million.

• Expect margin improvement in the remainder of 2025 and into 2026, driven by advanced imaging, mammography, and AI/TechLive implementation.